Ingevity Q1 sales rise 4% to $258.0M; GAAP EPS falls to $0.65, guidance reaffirmed
Ingevity reported first-quarter 2026 net sales of $258.0 million, up 4% from the prior year, while net income from continuing operations fell to $23.4 million, or $0.65 per diluted share, from $29.1 million and $0.79. The results include a $16.2 million litigation charge tied to legal fees payable to BASF, and the company reaffirmed its full-year 2026 guidance, adjusted for the Road Markings divestiture.
Key points
- Net sales were $258.0 million, up 4% from $247.9 million, driven mainly by pricing actions and favorable foreign exchange.
- Diluted EPS from continuing operations was $0.65 versus $0.79; the period included a $16.2 million litigation charge.
- Adjusted diluted EPS was $1.15 versus $1.01, and adjusted EBITDA was $91.5 million, flat year over year.
- Full-year 2026 outlook: net sales of $1.05 billion to $1.15 billion, adjusted EBITDA of $370 million to $395 million, and adjusted EPS of $4.70 to $5.20.
The filing
Written by AI on Nov 8, 2026, 1:54 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 06, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.